Related Experiment Video
Updated: Jul 30, 2025

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions
Published on: August 2, 2018
An antioxidant response element regulates the HIF1α axis in breast cancer cells
Sarah E Lacher1, Cara Skon-Hegg2, Brian L Ruis3
1Department of Biomedical Sciences, University of Minnesota Medical School, Duluth, MN, 55812, USA.
Abstract:
The redox sensitive transcription factor NRF2 is a central regulator of the transcriptional response to reactive oxygen species (ROS). NRF2 is widely recognized for its ROS-responsive upregulation of antioxidant genes that are essential for mitigating the damaging effects of oxidative stress. However, multiple genome-wide approaches have suggested that NRF2's regulatory reach extends well beyond the canonical antioxidant genes, with the potential to regulate many noncanonical target genes. Recent work from our lab and others suggests HIF1A, which encodes the hypoxia-responsive transcription factor HIF1α, is one such noncanonical NRF2 target. These studies found that NRF2 activity is associated with high HIF1A expression in multiple cellular contexts, HIF1A expression is partially dependent on NRF2, and there is a putative NRF2 binding site (antioxidant response element, or ARE) approximately 30 kilobases upstream of HIF1A. These findings all support a model in which HIF1A is a direct target of NRF2, but did not confirm the functional importance of the upstream ARE in HIF1A expression. Here we use CRISPR/Cas9 genome editing to mutate this ARE in its genomic context and test the impact on HIF1A expression. We find that mutation of this ARE in a breast cancer cell line (MDA-MB-231) eliminates NRF2 binding and decreases HIF1A expression at the transcript and protein levels, and disrupts HIF1α target genes as well as phenotypes driven by these HIF1α targets. Taken together, these results indicate that this NRF2 targeted ARE plays an important role in the expression of HIF1A and activity of the HIF1α axis in MDA-MB-231 cells.
Insights
The transcription factor NRF2 directly regulates HIF1A expression by binding to an upstream element, impacting cancer cell phenotypes. This study confirms NRF2
Area of Science:
- Molecular Biology
- Cancer Research
- Cellular Signaling
Background:
- NRF2 (Nuclear factor erythroid 2-related factor 2) is a key regulator of antioxidant genes in response to oxidative stress.
- Emerging evidence suggests NRF2 also targets noncanonical genes, including HIF1A (hypoxia-inducible factor 1-alpha).
- Previous studies indicated a link between NRF2 activity and HIF1A expression, with a potential NRF2 binding site upstream of HIF1A.
Purpose of the Study:
- To investigate the functional significance of a putative NRF2 binding site (antioxidant response element, ARE) upstream of the HIF1A gene.
- To determine if this ARE is critical for NRF2-mediated regulation of HIF1A expression and downstream effects.
Main Methods:
- CRISPR/Cas9 genome editing was employed to mutate the identified ARE in the HIF1A gene locus.
- The impact of ARE mutation on NRF2 binding, HIF1A mRNA and protein levels, and HIF1α target gene expression was assessed.
- Phenotypic consequences driven by HIF1α targets were evaluated in a breast cancer cell line.
Main Results:
- Mutation of the upstream ARE abolished NRF2 binding to the site.
- HIF1A transcript and protein levels were significantly decreased in cells with the mutated ARE.
- The expression of HIF1α target genes and associated cellular phenotypes were disrupted following ARE mutation.
Conclusions:
- The NRF2-targeted ARE upstream of HIF1A is functionally important for regulating HIF1A expression.
- NRF2 directly controls the HIF1α axis through this ARE, influencing cancer cell behavior.
- These findings highlight a novel regulatory pathway impacting cellular responses in breast cancer.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Regulation of the Unfolded Protein Response
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway

